Skip to main content
Premium Trial:

Request an Annual Quote

2022 Virtual Molecular Tumor Board Series

2022 virtual molecular tumor board series

 

About the Series

The 2022 Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Speakers

Howard McLeod webinar speaker profile image

Howard McLeod, PharmD

Medical Director, Precision Medicine
Geriatric Oncology Consortium

Read more

Dr. Howard McLeod is the Medical Director for Precision Medicine at the Geriatric Oncology Consortium. He is an internationally recognized expert in pharmacogenomics and personalized medicine, having made contributions at the discovery, translation, implementation, and policy levels. He is a Professor at the University of South Florida Taneja College of Pharmacy. He was previously the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He also chaired the Department of Individualized Cancer Management, was a Senior Member in the Department of Cancer Epidemiology, and a State of Florida Endowed Chair in Cancer Research. Dr. McLeod chaired the NHGRI eMERGE network external scientific panel for the past decade and was a recent member of both the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council.

Since 2002, Dr. McLeod has been vice chair for Pharmacogenomics for the major NCI clinical trials group, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is a Fellow of the American Society of Clinical Oncology and the American College of Clinical Pharmacy. Howard has published over 560 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance individualized medicine.

Lincoln Nadauld webinar speaker profile image

Lincoln Nadauld, MD, PhD

Chief, Precision Health and Genomics, Intermountain Healthcare

Read more

Lincoln Nadauld founded the Intermountain Precision Genomics program with a vision of finding solutions to improve health and disease through genomics and precision medicine without increasing costs. With his vision in mind, he oversees the clinical implementation of precision genomics across Intermountain’s 24 hospitals and 160 physician clinics. In addition, he facilitates genomic research to better understand the human genome. Nadauld conceived of and is leading the recently announced Heredigene, Population Study — a collaborative effort with deCODE Genetics in Iceland to collect and perform whole-genome sequencing on 500,000 participants in the Intermountain system. Nadauld’s work in founding Intermountain Precision Genomics was recognized with the Utah Governor’s 32nd Annual Science Medal for Industry, which is the highest civilian award to be bestowed by the state of Utah and honors significant contributions to science and technology. Dr. Nadauld also received the 2020 C2 Catalyst for Precision Medicine award, honoring those who improve personalized treatment for cancer patients. He is married with five children and enjoys attending their many activities and events, as well as water sports, fishing and other athletic pursuits.

Christine Walko webinar speaker profile image

Christine Walko, PharmD, BCOP, FCCP

Associate Member in the Department of Individualized Cancer Medicine and Program
Lead for the Precision Medicine Program at Moffitt Cancer Center

Read more

Christine M. Walko is a Personalized Medicine Specialist at the DeBartolo Family Personalized Medicine Institute at the H. Lee Moffitt Cancer Center and is also Associate Professor at the University of South Florida Morsani College of Medicine in Tampa, Florida. She is also the Chair of the Clinical Genomics Action Committee (CGAC) and an Attending on the Personalized Medicine Clinical Service at H. Lee Moffitt Cancer Center. Dr. Walko received her Doctor of Pharmacy from Duquesne University in Pittsburgh. She completed a pharmacy practice residency at Virginia Commonwealth University Health System/Medical College of Virginia Hospitals in Richmond, Virginia. She also completed a Hematology/Oncology specialty residency at the University of North Carolina (UNC) Hospitals and Clinics and a Hematology/Oncology fellowship at the University of North Carolina School of Pharmacy in Chapel Hill, North Carolina. She is a board-certified oncology pharmacist.

Jennifer Godden webinar speaker profile image

Jennifer Godden, PharmD, BCOP

Oncology Precision Medicine Senior Content Specialist, Wolters Kluwer

Read more

Jennifer Godden received her PharmD from the University of Iowa. She completed her post-graduate Pharmacy Practice and Oncology Specialty Residencies at Aurora Health Care. She is current the oncology precision medicine senior content specialist at Wolters Kluwer.

Laura Gonzalez webinar speaker profile image

Laura Gonzalez, PhD

Lead Variant Scientist, Intermountain Healthcare

Read more

Laura Gonzalez is lead variant scientist at Intermountain Healthcare. Prior to joining Intermountain, she held similar roles at Navican and the Virginia Commonwealth University Health System. She holds a BS and PhD from the School of Medicine at the National Autonomous University of Mexico.

Porscha Johnson Williams

Porscha Johnson Williams, Pharm.D.

Clinical Pharmacist
Northside Hospital of Atlanta

Read more

Dr. Porscha Johnson Williams is a graduate of the University of North Carolina at Chapel Hill, and received her Doctor of Pharmacy degree from Howard University College of Pharmacy in Washington, DC. Shefurthered her training through thecompletion ofa post-doctoral clinical pharmacy fellowship in Hematology/Oncology and Critical Care at Howard University Hospital. Currently, Porscha practices as a clinical pharmacist at Northside Hospital of Atlanta where she specializes in caring for medical oncology and bone marrow transplant patient populations. She collaborates with a multidisciplinaryteam for treatment decisions, and develops and maintains chemotherapy and supportive care protocols, policies and procedures according to cutting edge research within the field. Furthermore, Porscha oversees and contributes to many hospital-wide and department initiatives, the development and delivery of educational material and presentations to all disciplines, as well as serves as an independent consultant for pharmacogenomics to ensure the exceptional care for all patients.

Sessions

Multiomic Analyses and Cancer Therapy Selection

This webinar is part one of the four-part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which multiomic profiling has identified biomarkers that may or may not aid clinicians in making treatment decisions.

Precision oncology has seen a natural maturation from guiding therapy decisions based only on testing of specific, largely hotspot DNA mutations to testing that integrates assessment of sequence mutations, structural changes (i.e., deletions, amplifications, fusions), RNA, and protein levels. There are also genomic signatures, such as tumor mutation burden (TMB) and microsatellite instability (MSI), that have further clinical implications in a pan-solid tumor setting.

While these multiple layers of biomarker information have the potential to better inform individualized treatment plans and patient outcomes, they have also made it more difficult for oncologists to readily interpret test results and make clinical decisions. Our panel will discuss in detail several clinical cases where multiomic profiling was conducted and used to recommend a course of treatment for patients based on the available data.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now

Applying Tumor Homologous Recombination Deficiency in Practice

This webinar is part two of the four-part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency (HRD).

HRD is known to be a source of risk for heritable malignancies, such as breast and ovarian cancer. Increasing use of genomic sequencing combined with novel clinical development strategies is now expanding the types of cancer that are known to have an HRD subset and may respond to certain treatment regimens. 

Recently, oral PARP inhibitors have been approved, with the greatest activity observed in patients with HRD tumors. While a family of genes implicated in homologous recombination repair (HRR) have been associated with HRD (and related risk of malignancy), the impact of these genes on the activity of PARP inhibitors is still under study. This has increased the clinical challenges for interpretation of next-generation sequencing HRD results for many oncologists, as they try to keep up with which genes to act upon, when to refer a patient for genetic counseling, and how to prioritize HRD-associated therapy with other treatments that may be options based on a patient’s comprehensive genomic profile.

Our panel will address these challenges within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now

Impact of Structural Variants and Co-Occurring Variants on Cancer Therapy Prioritization

This webinar is part three of the four-part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified structural variants with possible clinical relevance.

Improvements in nucleic acid sequencing technology have made the routine detection of structural alterations such as gene fusions, amplifications, and genomic instability signatures possible. In particular, the clinical relevance of gene fusions has expanded, resulting in both FDA-approved and clinically supported treatment options. Additionally, the increased utilization of comprehensive genomic analyses has the potential to inform a broad range of co-occurring somatic and germline alterations that may be associated with hereditary disease, therapeutic selection, and resistance to treatments.

However, this technological progress has increased clinical challenges for oncologists, as they try to keep up with therapeutic opportunities and understand how to prioritize treatment options amid other biomarker-informed therapies that could also potentially benefit patients based on their comprehensive genomic profiling results.

Our panel will address these challenges and opportunities within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now

Therapeutic Options from RAS/MEK Pathway Alterations

This webinar is part four of our four-part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified activating mutations in the RAS or MEK pathways.

Molecular alterations in growth factor cell signaling pathways have been observed for most cancers and have led to novel treatment strategies. These pathways are often influenced by activating mutations in the RAS family and/or MEK-mediated signaling. There are now inhibitors of MEK and RAS family members (including the KRAS G12C mutation) with emerging clinical treatment strategies using novel combinations.

Clinical challenges for oncologists related to interpretation of these findings have increased as they try to keep up with the therapeutic options, specifically, when to apply them, and how to prioritize RAS/MEK related genes in the context of other alterations that are revealed in patients' comprehensive genomic profiling reports.

Our panel will address these challenges within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now